H&E staining reveals extensive infiltration of immune cells into treated breast tumors, which was associated with reduction in tumor growth and not observed in control tumors. See article by Sai and colleagues.

Read: First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies, Gregory L. Beatty, et al.

Read: Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient? Jessica R. Galloway-Peña, et al.